


IN THE CLAIMS

1.(original) Uracils having general formula (I):



(I)

wherein:

3 X_1 represents a hydrogen atom or a halogen atom;

4 X_2 represents a halogen atom;

- X_4 represents a C_1 - C_3 haloalkyl group;

- R represents a hydrogen atom, a C_1 - C_3 alkyl group or a C_1 - C_3 haloalkyl group;

- G represents an oxygen atom or a sulphur atom;

- X_3 represents a $Q(CR_1R_2)_nZ$ - group, a Q_1Z group, a Q_2 - group, a $Y(OC)-CR_6=CR_5-CR_3R_4Z$ - group;

- Z represents an oxygen atom or a sulphur atom;

- R_1 , R_2 , R_3 and R_4 , the same or different, represent a hydrogen atom, a C_1 - C_4 alkyl group or a C_1 - C_4 haloalkyl group;

- R₅ represents an OR₇ group;
- R₆ represents a hydrogen atom or a C₁-C₄ alkyl group;
- R₇ represents a C₁-C₄ alkyl group or a C₁-C₄ haloalkyl group;
- Y represents an OR₈ group, a SR₉ group, a NR₁₀R₁₁ group;
- R₈ and R₉ represent a hydrogen atom, a C₁-C₆ linear or branched alkyl group, a C₁-C₆ linear or branched haloalkyl group, a C₃-C₆ cycloalkyl group, a C₄-C₉ cycloalkylalkyl group, a C₃-C₆ cyanoalkyl group, a C₃-C₆ alkoxyalkyl group, an oxethanyl group, a tetrahydrofuranyl group; a phenyl group, a C₇-C₁₂ phenylalkyl group, a pyridyl group, said groups, in turn, possibly substituted with one or more halogen atoms selected from chlorine, fluorine, bromine or iodine, or substituted with one or more groups selected from C₁-C₄ alkyl, or C₁-C₄ haloalkyl, C₁-C₄ alkoxy or C₁-C₄ haloalkoxy;
- R₁₀ and R₁₁, the same or different, represent a hydrogen atom, or a C₁-C₆ alkyl group, a C₁-C₆ haloalkyl group, a C₃-C₆ cycloalkyl group, a C₇-C₁₂ arylalkyl group, or an aryl group, said groups, in turn, possibly substituted with one or more halogen atoms selected from chlorine, fluorine, bromine or iodine, or substituted with one or more groups selected from a C₁-C₄ alkyl, or C₁-C₄

haloalkyl, C₁-C₄ alkoxy or C₁-C₄ haloalkoxy; or, jointly represent a C₂-C₇ alkylene chain possibly substituted with C₁-C₄ alkyl groups and possibly interrupted by oxygen atoms or by a NR₁₂ group, wherein:

- R₁₂ represents a hydrogen atom, a C₁-C₆ alkyl group or C₁-C₆ haloalkyl group, a C₃-C₆ alkenyl group or a C₃-C₆ haloalkenyl group, a C₃-C₆ alkynyl group or C₃-C₆ haloalkynyl group, a C₂-C₈ alkoxyalkyl group or a C₂-C₈ haloalkoxyalkyl group, a C₂-C₇ alkylcarbonyl group or C₂-C₇ haloalkylcarbonyl group:
- n represents 1, 2 or 3;
- Q represents a heterocyclic group selected from pyrrol-2-yl, pyrrol-3-yl, imidazol-2-yl, imidazol-4-yl, imidazol-5-yl, pyrazol-3-yl, pyrazol-4-yl, pyrazol-5-yl, 1,2,4-triazol-3-yl, 1,2,4-triazol-5-yl, 1,2,4-triazol-3-onyl, 1,2,3-triazolyl, tetrazolyl, oxazolyl, isoxazol-5-yl, thiazol-2-yl, thiazol-5-yl, isothiazolyl, 1,3,4-oxadiazolyl, 1,3,4-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,4-oxadiazolyl, 1,2,4-oxadiazol-5-on-3-yl, benzoxazol-2-yl, benzothiazol-2-yl, pyrazinyl, pyridazinyl, 1,2,4-triazinyl, 1,3,4-thiadiazol-2-on-5-yl, 1,4,2-dioxazol-5-on-3-yl, 1,4,2-oxathiazol-5-on-3-yl, 1,3,4-oxadiazin-5-on-2-yl, 1,4,2-dioxazin-3-yl, 1,2,4-oxadiazin-5-on-3-yl, 4,5,6,7-

tetrahydro-1,3-benzothiazol-2-yl, 5,6-dihydro-4H-cyclopenta[d][1,3]thiazole, said groups, in turn, possibly substituted with halogen atoms selected from chlorine, fluorine, bromine or iodine, or substituted with groups selected from C₁-C₆ alkyl or C₁-C₆ haloalkyl, C₂-C₆ alkenyl or C₂-C₆ haloalkenyl, C₂-C₆ alkenyloxy or C₂-C₆ haloalkenyloxy, C₂-C₆ alkynyl or C₂-C₆ haloalkynyl, C₂-C₆ alkynyloxy or C₂-C₆ haloalkynyloxy, C₁-C₆ alkoxy or C₁-C₆ haloalkoxy, C₂-C₆ alkoxyalkyl or C₂-C₆ haloalkoxyalkyl, C₂-C₆ alkoxyalkoxy, C₂-C₆ haloalkoxyalkoxy, C₃-C₈ alkoxyalkoxyalkyl, C₃-C₈ alkoxyalkoxyalkoxy, C₁-C₆ alkylthio or C₁-C₆ haloalkylthio, C₂-C₆ alkylthioalkyl, C₁-C₆ alkylsulfinic or C₁-C₆ haloalkylsulfinic, C₁-C₆ alkylsulfonic or C₁-C₆ haloalkylsulfonic, C₂-C₆ alkoxycarbonyl or C₂-C₆ haloalkoxycarbonyl, C₃-C₇ alkenyloxycarbonyl or C₃-C₇ alkynyloxycarbonyl, C₃-C₈ alkoxycarbonylalkyl or C₃-C₈ haloalkoxycarbonylalkyl, C₄-C₉ alkenyloxycarbonylalkyl or C₄-C₉ alkynyloxycarbonylalkyl, C₃-C₈ alkoxycarbonylalkoxy, C₄-C₉ alkenyloxycarbonylalkoxy or C₄-C₉ alkynyloxycarbonylalkoxy, C₃-C₈ aminocarbonylalkoxy possibly substituted with C₁-C₄ alkyl groups or with a C₂-C₅ alkylene group; CN, CHO, NO₂, NH₂, OH, C₁-C₃

cyanoalkyl, C₁-C₃ cyanoalkyloxy, C₂-C₆ formylalkyl, C₂-C₆ alkylcarbonyl, C₂-C₆ haloalkylcarbonyl, C₃-C₇ alkylcarbonylalkyl, C₂-C₆ alkoxyimino, C₂-C₆ haloalkoxyimino, C₃-C₆ alkoxyiminoalkyl, C₃-C₆ haloalkoxyiminoalkyl, C₃-C₆ alkoxyiminohaloalkyl, aminocarbonyl, C₂-C₆ aminocarbonylalkyl, aminosulfonyl or C₂-C₆ aminosulfonylalkyl, these last four groups possibly substituted with one or two C₁-C₄ alkyl groups or with a C₂-C₅ alkylene group; C₁-C₆ alkylsulfonylamino, C₂-C₇ alkylcarbonylamino or C₂-C₇ alkoxy carbonylamino, these last three groups possibly substituted with C₁-C₄ alkyl groups; C₆-C₁₀ aryl, C₆-C₁₂ arylalkyl, C₆-C₁₀ arylalkoxy, C₇-C₁₂ aryloxyalkyl, C₈-C₁₂ arylalkyloxyalkyl said groups in turn possibly substituted with halogen atoms, C₁-C₄ alkyl groups, C₁-C₃ haloalkyl groups, C₁-C₄ alkoxy groups, C₁-C₃ haloalkoxy groups, CN; C₃-C₇ cycloalkyl, C₆-C₁₂ cycloalkylalkyl, C₆-C₁₀ cycloalkylalkoxy, tetrahydropyran-2-yl said groups in turn possibly substituted with halogen atoms, C₁-C₄ alkyl groups, C₁-C₄ alkoxy groups;

- Q₁ represents a heterocyclic group selected from 1,3,4-thiadiazol-2-yl, 1,3,4-thiadiazol-5-yl, 1,2,4-thiadiazol-5-yl, tetrazol-5-yl, 1,3,4-oxadiazol-2-yl, 1,3,4-oxadiazol-5-yl, 1,2,4-oxadiazol-5-yl, oxazol-2-

yl, oxazol-4-yl, oxazol-5-yl, isoxazol-3-yl, isoxazol-5-yl, thiazol-2-yl, thiazol-4-yl, thiazol-5-yl, said groups, in turn, possibly substituted with halogen atoms selected from chlorine, fluorine, bromine or iodine, or substituted with groups selected from C₁-C₆ alkyl or C₁-C₆ haloalkyl, C₂-C₆ alkenyl or C₂-C₆ haloalkenyl, C₂-C₆ alkenyloxy or C₂-C₆ haloalkenyloxy, C₂-C₆ alkynyl or C₂-C₆ haloalkynyl, C₂-C₆ alkynyloxy or C₂-C₆ haloalkynyloxy, C₁-C₆ alkoxy or C₁-C₆ haloalkoxy, C₂-C₆ alkoxyalkyl or C₂-C₆ haloalkoxyalkyl, C₁-C₆ alkylthio or C₁-C₆ haloalkylthio, C₁-C₆ alkylsulfinic or C₁-C₆ haloalkylsulfinic, C₁-C₆ alkylsulfonic or C₁-C₆ haloalkylsulfonic, C₂-C₆ alkoxycarbonyl or C₂-C₆ haloalkoxycarbonyl, C₃-C₈ alkoxycarbonylalkyl or C₃-C₈ haloalkoxycarbonylalkyl, C₃-C₈ alkoxycarbonylalkoxy, C₃-C₈ aminocarbonylalkoxy possibly substituted with C₁-C₄ alkyl groups or with a C₂-C₅ alkylene; CN, CHO, NO₂, NH₂, C₁-C₃ cyanoalkyl, C₁-C₃ cyanoalkyloxy, C₂-C₆ alkylcarbonyl, C₂-C₆ haloalkylcarbonyl, C₃-C₆ alkoxyiminoalkyl, C₃-C₆ haloalkoxyiminoalkyl, aminocarbonyl, C₂-C₆ aminocarbonylalkyl, aminosulfonyl or C₂-C₆ aminosulfonylalkyl, these last four groups possibly substituted with one or two C₁-C₄ alkyl groups or with a C₂-C₅ alkylene; C₁-C₆ alkylsulfonylamino, C₂-C₇

alkylcarbonylamino or C₂-C₇ alkoxy carbonylamino, these last three groups possibly substituted with C₁-C₄ alkyl groups; C₆-C₁₀ aryl, C₆-C₁₂ arylalkyl, C₆-C₁₀ arylalkoxy, C₇-C₁₂ aryloxyalkyl, C₈-C₁₂ arylalkyloxyalkyl said groups in turn possibly substituted with halogen atoms, C₁-C₄ alkyl groups, C₁-C₃ haloalkyl groups, C₁-C₄ alkoxy groups, C₁-C₃ haloalkoxy groups, CN; C₃-C₇ cycloalkyl, C₆-C₁₂ cycloalkylalkyl, C₆-C₁₀ cycloalkylalkoxy, tetrahydropyran-2-yl said groups in turn possibly substituted with halogen atoms, C₁-C₄ alkyl groups, C₁-C₄ alkoxy groups;

- Q₂ represents a heterocyclic group selected from tetrazol-5-yl, thiazol-2-yl, thiazol-4-yl, thiazol-5-yl, isothiazol-3-yl, isothiazol-4-yl, isothiazol-5-yl, 1,2,3-triazolyl, benzoxazol-2-yl, benzothiazol-2-yl, pyrimidin-2-yl, 1,2,4-triazinyl, 1,3,5-triazinyl, 1,3,4-thiadiazol-2-on-5-yl, 1,4,2-dioxazol-5-on-3-yl, 1,4,2-oxathiazol-5-on-3-yl, 1,3,4-oxadiazin-5-on-2-yl, 1,4,2-dioxazin-3-yl, 1,2,4-oxadiazin-5-on-3-yl, 4,5,6,7-tetrahydro-1,3-benzothiazol-2-yl, 5,6-dihydro-4*H*-cyclopenta[*d*][1,3]thiazole, said groups in turn possibly substituted with halogen atoms selected from chlorine, fluorine, bromine or iodine, or substituted with groups selected from C₁-C₆ alkyl or C₁-C₆ haloalkyl,

C₂-C₆ alkenyl or C₂-C₆ haloalkenyl, C₂-C₆ alkenyloxy or
 C₂-C₆ haloalkenyloxy, C₂-C₆ alkynyl or C₂-C₆ haloalkynyl,
 C₂-C₆ alkynyloxy or C₂-C₆ haloalkynyloxy, C₁-C₆ alkoxy or
 C₁-C₆ haloalkoxy, C₂-C₆ alkoxyalkyl or C₂-C₆
 haloalkoxyalkyl, C₂-C₆ alkoxyalkoxy, C₂-C₆
 haloalkoxyalkoxy, C₂-C₆ haloalkoxyhaloalkoxy, C₃-C₈
 alkoxyalkoxyalkyl, C₃-C₈ alkoxyalkoxyalkoxy, C₁-C₆
 alkylthio or C₁-C₆ haloalkylthio, C₂-C₆ alkylthioalkyl,
 C₁-C₆ alkylsulfinic or C₁-C₆ haloalkylsulfinic, C₁-C₆
 alkylsulfonic or C₁-C₆ haloalkylsulfonic, C₂-C₆
 alkoxycarbonyl or C₂-C₆ haloalkoxycarbonyl, C₃-C₇
 alkenyloxycarbonyl or C₃-C₇ alkynyloxycarbonyl, C₃-C₈
 alkoxycarbonylalkyl or C₃-C₈ haloalkoxycarbonylalkyl,
 C₄-C₉ alkenyloxycarbonylalkyl or C₄-C₉
 alkynyloxycarbonylalkyl, C₃-C₈ alkoxycarbonylalkoxy,
 alkenyloxycarbonylalkoxy C₄-C₉ or
 alkynyloxycarbonylalkoxy C₄-C₉, C₃-C₈
 aminocarbonylalkoxy possibly substituted with C₁-C₄
 alkyl or with a C₂-C₅ alkylene; CN, CHO, NO₂, NH₂, OH,
 C₁-C₃ cyanoalkyl, C₁-C₃ cyanoalkyloxy, C₂-C₆ formylalkyl,
 C₂-C₆ alkylcarbonyl, C₂-C₆ haloalkylcarbonyl, C₃-C₇
 alkylcarbonylalkyl, C₂-C₆ alkoxyimino, C₂-C₆
 haloalkoxyimino, C₃-C₆ alkoxyiminoalkyl, C₃-C₆
 haloalkoxyiminoalkyl, alkoxyiminohaloalkyl C₃-C₆,

aminocarbonyl, C₂-C₆ aminocarbonylalkyl, aminosulfonyl or C₂-C₆ aminosulfonylalkyl, these last four groups possibly substituted with one or two C₁-C₄ alkyl groups or with a C₂-C₅ alkylene; C₁-C₆ alkylsulfonylamino, C₂-C₇ alkylcarbonylamino or C₂-C₇ alkoxy carbonylamino, these last three groups possibly substituted with C₁-C₄ alkyl groups; C₆-C₁₀ aryl, C₆-C₁₂ arylalkyl, C₆-C₁₀ arylalkoxy, C₇-C₁₂ aryloxyalkyl, C₈-C₁₂ arylalkyloxyalkyl said groups in turn possibly substituted with halogen atoms, C₁-C₄ alkyl groups, C₁-C₃ haloalkyl groups, C₁-C₄ alkoxy groups, C₁-C₃ haloalkoxy groups, CN; C₃-C₇ cycloalkyl, C₆-C₁₂ cycloalkylalkyl, C₆-C₁₀ cycloalkylalkoxy, tetrahydropyran-2-yl said groups in turn possibly substituted with halogen atoms, C₁-C₄ alkyl groups, C₁-C₄ alkoxy groups.

2.(original): The uracils according to claim 1, characterized in that they are selected from:

- methyl (2*E*)-4-{2-chloro-4-fluoro-5-[1,2,3,6-tetrahydro-3-methyl-2,6-dioxo-4-(trifluoromethyl)pyrimidin-1-yl]phenoxy}-3-methoxybut-2-enoate;
- methyl (2*E*)-4-{2,4-dichloro-5-[1,2,3,6-tetrahydro-3-methyl-2,6-dioxo-4-(trifluoromethyl)pyrimidin-1-yl]phenoxy}-3-methoxybut-2-enoate;
- methyl (2*E*)-4-{2-chloro-4-fluoro-5-[1,2,3,6-tetrahydro-3-

methyl-2,6-dioxo-4-(trifluoromethyl)pyrimidin-1-yl]phenylthio}-3-methoxybut-2-enoate;
 - ethyl (2E)-4-{2-chloro-4-fluoro-5-[1,2,3,6-tetrahydro-3-methyl-2,6-dioxo-4-(trifluoromethyl)pyrimidin-1-yl]phenoxy}-3-ethoxybut-2-enoate;
 - methyl (2E)-4-{2,4-dichloro-5-[1,2,3,6-tetrahydro-3-methyl-2,6-dioxo-4-(trifluoromethyl)pyrimidin-1-yl]phenylthio}-3-methoxybut-2-enoate;
 - ethyl (2E)-4-{2,4-dichloro-5-[1,2,3,6-tetrahydro-3-methyl-2,6-dioxo-4-(trifluoromethyl)pyrimidin-1-yl]phenoxy}-3-ethoxybut-2-enoate;
 - isopropyl (2E)-4-{2-chloro-4-fluoro-5-[1,2,3,6-tetrahydro-3-methyl-2,6-dioxo-4-(trifluoromethyl)pyrimidin-1-yl]phenoxy}-3-methoxybut-2-enoate;
 - methyl (2E)-4-{2-chloro-4-fluoro-5-[1,2,3,6-tetrahydro-2,6-dioxo-4-(trifluoromethyl)pyrimidin-1-yl]phenoxy}-3-methoxybut-2-enoate;
 - methyl (2E)-4-{2,4-dichloro-5-[1,2,3,6-tetrahydro-2,6-dioxo-4-(trifluoromethyl)pyrimidin-1-yl]phenoxy}-3-methoxybut-2-enoate;
 - ethyl (2E)-4-{2-chloro-4-fluoro-5-[1,2,3,6-tetrahydro-2,6-dioxo-4-(trifluoromethyl)pyrimidin-1-yl]phenoxy}-3-ethoxybut-2-enoate;
 - ethyl (2E)-4-{2,4-dichloro-5-[1,2,3,6-tetrahydro-2,6-

dioxo-4-(trifluoromethyl)pyrimidin-1-yl]phenoxy}-3-ethoxybut-2-enoate;

- 2,2,2-trifluoroethyl (2E)-4-{2-chloro-4-fluoro-5-[1,2,3,6-tetrahydro-2,6-dioxo-4-(trifluoromethyl)pyrimidin-1-yl]phenoxy}-3-methoxybut-2-enoate;
- (2E)-4-{2-chloro-4-fluoro-5-[1,2,3,6-tetrahydro-2,6-dioxo-4-(trifluoromethyl)pyrimidin-1-yl]phenoxy}-3-methoxy-N,N-dimethylbut-2-enamide;
- S-ethyl (2E)-4-{2-chloro-4-fluoro-5-[1,2,3,6-tetrahydro-2,6-dioxo-4-(trifluoromethyl)pyrimidin-1-yl]phenoxy}-3-methoxybut-2-enethioate;
- isopropyl (2E)-4-{2,4-dichloro-5-[1,2,3,6-tetrahydro-3-methyl-2,6-dioxo-4-(trifluoromethyl)pyrimidin-1-yl]phenoxy}-3-methoxybut-2-enoate;
- 2,2,2-trifluoroethyl (2E)-4-{2-chloro-4-fluoro-5-[1,2,3,6-tetrahydro-3-methyl-2,6-dioxo-4-(trifluoromethyl)pyrimidin-1-yl]phenoxy}-3-methoxybut-2-enoate;
- 2,2,2-trifluoroethyl (2E)-4-{2,4-dichloro-5-[1,2,3,6-tetrahydro-3-methyl-2,6-dioxo-4-(trifluoromethyl)pyrimidin-1-yl]phenoxy}-3-methoxybut-2-enoate;
- S-ethyl (2E)-4-{2-chloro-4-fluoro-5-[1,2,3,6-tetrahydro-3-methyl-2,6-dioxo-4-(trifluoromethyl)pyrimidin-1-yl]phenoxy}-3-methoxybut-2-enethioate;
- S-ethyl (2E)-4-{2,4-dichloro-5-[1,2,3,6-tetrahydro-3-

methyl-2,6-dioxo-4-(trifluoromethyl)pyrimidin-1-yl]phenoxy}-3-methoxybut-2-enethioate;
 - (2E)-4-{2-chloro-4-fluoro-5-[1,2,3,6-tetrahydro-3-methyl-2,6-dioxo-4-(trifluoromethyl)pyrimidin-1-yl]phenoxy}-3-methoxy-N,N-dimethylbut-2-enamide;
 - (2E)-4-{2,4-dichloro-5-[1,2,3,6-tetrahydro-3-methyl-2,6-dioxo-4-(trifluoromethyl)pyrimidin-1-yl]phenoxy}-3-methoxy-N,N-dimethylbut-2-enamide;
 - (2E)-4-{2-chloro-4-fluoro-5-[1,2,3,6-tetrahydro-3-methyl-2,6-dioxo-4-(trifluoromethyl)pyrimidin-1-yl]phenylthio}-3-methoxy-N,N-dimethylbut-2-enamide;
 - (2E)-4-{2,4-dichloro-5-[1,2,3,6-tetrahydro-3-methyl-2,6-dioxo-4-(trifluoromethyl)pyrimidin-1-yl]phenylthio}-3-methoxy-N,N-dimethylbut-2-enamide;
 - 3-[4-chloro-2-fluoro-5-(tetrazol-5-ylmethoxy)phenyl]-6-(trifluoromethyl)-2,4(1H,3H)-pyrimidinedione;
 - 3-{4-chloro-2-fluoro-5-[(2-methyl-2H-tetrazol-5-yl)methoxy]phenyl}-6-(trifluoromethyl)-2,4(1H,3H)-pyrimidinedione;
 - 3-[4-chloro-2-fluoro-5-(tetrazol-5-ylmethoxy)phenyl]-1-methyl-6-(trifluoromethyl)-2,4(1H,3H)-pyrimidinedione;
 - 3-[2,4-dichloro-5-(tetrazol-5-ylmethoxy)phenyl]-1-methyl-6-(trifluoromethyl)-2,4(1H,3H)-pyrimidinedione;
 - 3-{4-chloro-2-fluoro-5-[(2-methyl-2H-tetrazol-5-

yl)methoxy]phenyl}-1-methyl-6-(trifluoromethyl)-2,4(1*H*,3*H*)-pyrimidinedione;

- 3-{4-chloro-2-fluoro-5-[(2-ethyl-2*H*-tetrazol-5-yl)methoxy]phenyl}-1-methyl-6-(trifluoromethyl)-2,4(1*H*,3*H*)-pyrimidinedione;
- 3-{2,4-dichloro-5-[(2-methyl-2*H*-tetrazol-5-yl)methoxy]phenyl}-1-methyl-6-(trifluoromethyl)-2,4(1*H*,3*H*)-pyrimidinedione;
- 3-{2,4-dichloro-5-[(2-ethyl-2*H*-tetrazol-5-yl)methoxy]phenyl}-1-methyl-6-(trifluoromethyl)-2,4(1*H*,3*H*)-pyrimidinedione;
- 3-{4-chloro-2-fluoro-5-[(1-ethyl-1*H*-tetrazol-5-yl)methoxy]phenyl}-1-methyl-6-(trifluoromethyl)-2,4(1*H*,3*H*)-pyrimidinedione;
- 3-{2,4-dichloro-5-[(1-ethyl-1*H*-tetrazol-5-yl)methoxy]phenyl}-1-methyl-6-(trifluoromethyl)-2,4(1*H*,3*H*)-pyrimidinedione;
- 3-{5-[(5-*tert*-butyl-1,3,4-oxadiazol-2-yl)methoxy]-4-chloro-2-fluorophenyl}-1-methyl-6-(trifluoromethyl)-2,4(1*H*,3*H*)-pyrimidinedione;
- methyl [5-({2-chloro-4-fluoro-5-[1,2,3,6-tetrahydro-3-methyl-2,6-dioxo-4-(trifluoromethyl)pyrimidin-1-yl]phenoxy)methyl}-1*H*-tetrazol-1-yl]acetate;
- methyl [5-({2,4-dichloro-5-[1,2,3,6-tetrahydro-3-methyl-

2,6-dioxo-4-(trifluoromethyl)pyrimidin-1-yl]phenoxy)methyl)-1*H*-tetrazol-1-yl]acetate;

- methyl [5-({2-chloro-4-fluoro-5-[1,2,3,6-tetrahydro-3-methyl-2,6-dioxo-4-(trifluoromethyl)pyrimidin-1-yl]phenoxy)methyl)-2*H*-tetrazol-2-yl]acetate;
- methyl [5-({2,4-dichloro-5-[1,2,3,6-tetrahydro-3-methyl-2,6-dioxo-4-(trifluoromethyl)pyrimidin-1-yl]phenoxy)methyl)-2*H*-tetrazol-2-yl]acetate;
- 3-[4-chloro-3-(tetrazol-5-yl)phenyl]-6-(trifluoromethyl)-2,4(1*H*,3*H*)-pyrimidinedione;
- 3-[4-chloro-3-(2-methyl-2*H*-tetrazol-5-yl)phenyl]-6-(trifluoromethyl)-2,4(1*H*,3*H*)-pyrimidinedione;
- 3-[4-chloro-3-(1-methyl-1*H*-tetrazol-5-yl)phenyl]-6-(trifluoromethyl)-2,4(1*H*,3*H*)-pyrimidinedione;
- 3-[4-chloro-3-(tetrazol-5-yl)phenyl]-1-methyl-6-(trifluoromethyl)-2,4(1*H*,3*H*)-pyrimidinedione;
- 3-[4-chloro-2-fluoro-5-(tetrazol-5-yl)phenyl]-6-(trifluoromethyl)-2,4(1*H*,3*H*)-pyrimidinedione;
- 3-[2,4-dichloro-5-(tetrazol-5-yl)phenyl]-6-(trifluoromethyl)-2,4(1*H*,3*H*)-pyrimidinedione;
- 3-[4-chloro-2-fluoro-5-(tetrazol-5-yl)phenyl]-1-methyl-6-(trifluoromethyl)-2,4(1*H*,3*H*)-pyrimidinedione;
- 3-[2,4-dichloro-5-(tetrazol-5-yl)phenyl]-1-methyl-6-(trifluoromethyl)-2,4(1*H*,3*H*)-pyrimidinedione;

- 3-[4-chloro-3-(2-methyl-2*H*-tetrazol-5-yl)phenyl]-1-methyl-6-(trifluoromethyl)-2,4(1*H*,3*H*)-pyrimidinedione;
- 3-[4-chloro-2-fluoro-5-(2-methyl-2*H*-tetrazol-5-yl)phenyl]-6-(trifluoromethyl)-2,4(1*H*,3*H*)-pyrimidinedione;
- 3-[2,4-dichloro-5-(2-methyl-2*H*-tetrazol-5-yl)phenyl]-6-(trifluoromethyl)-2,4(1*H*,3*H*)-pyrimidinedione;
- 3-[4-chloro-2-fluoro-5-(1-methyl-1*H*-tetrazol-5-yl)phenyl]-6-(trifluoromethyl)-2,4(1*H*,3*H*)-pyrimidinedione;
- 3-[2,4-dichloro-5-(1-methyl-1*H*-tetrazol-5-yl)phenyl]-6-(trifluoromethyl)-2,4(1*H*,3*H*)-pyrimidinedione;
- 3-[4-chloro-2-fluoro-5-(2-methyl-2*H*-tetrazol-5-yl)phenyl]-1-methyl-6-(trifluoromethyl)-2,4(1*H*,3*H*)-pyrimidinedione;
- 3-[2,4-dichloro-5-(2-methyl-2*H*-tetrazol-5-yl)phenyl]-1-methyl-6-(trifluoromethyl)-2,4(1*H*,3*H*)-pyrimidinedione;
- 3-[4-chloro-3-(2-ethyl-2*H*-tetrazol-5-yl)phenyl]-1-methyl-6-(trifluoromethyl)-2,4(1*H*,3*H*)-pyrimidinedione;
- 3-[4-chloro-3-(1-methyl-1*H*-tetrazol-5-yl)phenyl]-1-methyl-6-(trifluoromethyl)-2,4(1*H*,3*H*)-pyrimidinedione;
- 3-[4-chloro-2-fluoro-5-(1-methyl-1*H*-tetrazol-5-yl)phenyl]-1-methyl-6-(trifluoromethyl)-2,4(1*H*,3*H*)-pyrimidinedione;
- 3-[2,4-dichloro-5-(1-methyl-1*H*-tetrazol-5-yl)phenyl]-1-methyl-6-(trifluoromethyl)-2,4(1*H*,3*H*)-pyrimidinedione;

- 3-[4-chloro-3-(1-ethyl-1*H*-tetrazol-5-yl)phenyl]-1-methyl-6-(trifluoromethyl)-2,4(1*H*,3*H*)-pyrimidinedione;
- methyl (5-{2-chloro-5-[1,2,3,6-tetrahydro-3-methyl-2,6-dioxo-4-(trifluoromethyl)pyrimidin-1-yl]phenyl}-1*H*-tetrazol-1-yl)acetate;
- methyl (5-{2-chloro-5-[1,2,3,6-tetrahydro-3-methyl-2,6-dioxo-4-(trifluoromethyl)pyrimidin-1-yl]phenyl}-2*H*-tetrazol-2-yl)acetate;
- methyl (5-{2-chloro-4-fluoro-5-[1,2,3,6-tetrahydro-3-methyl-2,6-dioxo-4-(trifluoromethyl)pyrimidin-1-yl]phenyl}-1*H*-tetrazol-1-yl)acetate;
- methyl (5-{2-chloro-4-fluoro-5-[1,2,3,6-tetrahydro-3-methyl-2,6-dioxo-4-(trifluoromethyl)pyrimidin-1-yl]phenyl}-2*H*-tetrazol-2-yl)acetate;
- methyl (5-{2,4-dichloro-5-[1,2,3,6-tetrahydro-3-methyl-2,6-dioxo-4-(trifluoromethyl)pyrimidin-1-yl]phenyl}-1*H*-tetrazol-1-yl)acetate;
- methyl (5-{2,4-dichloro-5-[1,2,3,6-tetrahydro-3-methyl-2,6-dioxo-4-(trifluoromethyl)pyrimidin-1-yl]phenyl}-2*H*-tetrazol-2-yl)acetate;
- 3-[4-chloro-3-(4-methoxy-5-methyl-1,3-thiazol-2-yl)phenyl]-6-(trifluoromethyl)-2,4(1*H*,3*H*)-pyrimidinedione;
- 3-[2,4-dichloro-5-(4-methoxy-5-methyl-1,3-thiazol-2-yl)phenyl]-6-(trifluoromethyl)-2,4(1*H*,3*H*)-pyrimidinedione;

- 3-[4-chloro-2-fluoro-5-(4-methoxy-5-methyl-1,3-thiazol-2-yl)phenyl-6-(trifluoromethyl)-2,4(1*H*,3*H*)-pyrimidinedione;
- 3-[4-chloro-3-(4-methoxy-5-methyl-1,3-thiazol-2-yl)phenyl-1-methyl-6-(trifluoromethyl)-2,4(1*H*,3*H*)-pyrimidinedione;
- 3-[4-chloro-3-(4-ethoxy-5-methyl-1,3-thiazol-2-yl)phenyl-1-methyl-6-(trifluoromethyl)-2,4(1*H*,3*H*)-pyrimidinedione;
- 3-[2,4-dichloro-5-(4-methoxy-5-methyl-1,3-thiazol-2-yl)phenyl-1-methyl-6-(trifluoromethyl)-2,4(1*H*,3*H*)-pyrimidinedione;
- 3-[2,4-dichloro-5-(4-ethoxy-5-methyl-1,3-thiazol-2-yl)phenyl-1-methyl-6-(trifluoromethyl)-2,4(1*H*,3*H*)-pyrimidinedione;
- 3-[4-chloro-2-fluoro-5-(4-methoxy-5-methyl-1,3-thiazol-2-yl)phenyl-1-methyl-6-(trifluoromethyl)-2,4(1*H*,3*H*)-pyrimidinedione;
- 3-[4-chloro-2-fluoro-5-(4-ethoxy-5-methyl-1,3-thiazol-2-yl)phenyl-1-methyl-6-(trifluoromethyl)-2,4(1*H*,3*H*)-pyrimidinedione;
- 3-[4-chloro-3-(4-benzyloxy-5-methyl-1,3-thiazol-2-yl)phenyl-1-methyl-6-(trifluoromethyl)-2,4(1*H*,3*H*)-pyrimidinedione;
- 3-[2,4-dichloro-5-(4-benzyloxy-5-methyl-1,3-thiazol-2-yl)phenyl-1-methyl-6-(trifluoromethyl)-2,4(1*H*,3*H*)-pyrimidinedione;

pyrimidinedione;

- 3-[4-chloro-2-fluoro-5-(4-benzyloxy-5-methyl-1,3-thiazol-2-yl)phenyl-1-methyl-6-(trifluoromethyl)-2,4(1H,3H)-

pyrimidinedione;

- 3-(2,4-dichloro-5-{[5-(trifluoromethyl)-1,3,4-thiadiazol-2-yl]oxy}phenyl)-6-(trifluoromethyl)-2,4(1H,3H)-

pyrimidinedione;

- 3-(4-chloro-2-fluoro-5-{[5-(trifluoromethyl)-1,3,4-thiadiazol-2-yl]oxy}phenyl)-6-(trifluoromethyl)-2,4(1H,3H)-

pyrimidinedione;

- 3-(2,4-dichloro-5-{[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]oxy}phenyl)-6-(trifluoromethyl)-2,4(1H,3H)-

pyrimidinedione;

- 3-(4-chloro-2-fluoro-5-{[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]oxy}phenyl)-6-(trifluoromethyl)-2,4(1H,3H)-

pyrimidinedione;

- 3-(4-chloro-3-{[5-(trifluoromethyl)-1,3,4-thiadiazol-2-yl]oxy}phenyl)-1-methyl-6-(trifluoromethyl)-2,4(1H,3H)-

pyrimidinedione;

- 3-(2,4-dichloro-5-{[5-(trifluoromethyl)-1,3,4-thiadiazol-2-yl]oxy}phenyl)-1-methyl-6-(trifluoromethyl)-2,4(1H,3H)-

pyrimidinedione;

- 3-(4-chloro-2-fluoro-5-{[5-(trifluoromethyl)-1,3,4-thiadiazol-2-yl]oxy}phenyl)-1-methyl-6-(trifluoromethyl)-

2,4(1*H*,3*H*)-pyrimidinedione;

- 3-{4-chloro-3-[(5-methyl-1,3,4-thiadiazol-2-yl)oxy]phenyl}-1-methyl-6-(trifluoromethyl)-2,4(1*H*,3*H*)-pyrimidinedione;
- 3-{2,4-dichloro-5-[(5-methyl-1,3,4-thiadiazol-2-yl)oxy]phenyl}-1-methyl-6-(trifluoromethyl)-2,4(1*H*,3*H*)-pyrimidinedione;
- 3-{4-chloro-2-fluoro-5-[(5-methyl-1,3,4-thiadiazol-2-yl)oxy]phenyl}-1-methyl-6-(trifluoromethyl)-2,4(1*H*,3*H*)-pyrimidinedione;
- 3-(4-chloro-3-{[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]oxy}phenyl)-1-methyl-6-(trifluoromethyl)-2,4(1*H*,3*H*)-pyrimidinedione;
- 3-(2,4-dichloro-5-{[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]oxy}phenyl)-1-methyl-6-(trifluoromethyl)-2,4(1*H*,3*H*)-pyrimidinedione;
- 3-(4-chloro-2-fluoro-5-{[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]oxy}phenyl)-1-methyl-6-(trifluoromethyl)-2,4(1*H*,3*H*)-pyrimidinedione;
- 3-{4-chloro-3-[(5-methyl-1,3,4-oxadiazol-2-yl)oxy]phenyl}-1-methyl-6-(trifluoromethyl)-2,4(1*H*,3*H*)-pyrimidinedione;
- 3-{2,4-dichloro-5-[(5-methyl-1,3,4-oxadiazol-2-yl)oxy]phenyl}-1-methyl-6-(trifluoromethyl)-2,4(1*H*,3*H*)-

pyrimidinedione;

- 3-{4-chloro-2-fluoro-5-[(5-methyl-1,3,4-oxadiazol-2-yl)oxy]phenyl}-1-methyl-6-(trifluoromethyl)-2,4(1*H*,3*H*)-

pyrimidinedione;

- methyl (2*E*)-4-{2-chloro-4-fluoro-5-[1,2,3,6-tetrahydro-3-methyl-6-oxo-2-thioxo-4-(trifluoromethyl)pyrimidin-1-yl]phenoxy}-3-methoxybut-2-enoate;

- methyl (2*E*)-4-{2-chloro-4-fluoro-5-[1,2,3,6-tetrahydro-3-difluoromethyl-2,6-dioxo-4-(trifluoromethyl)pyrimidin-1-yl]phenoxy}-3-methoxybut-2-enoate;

- 3-[4-chloro-3-(4,5-dimethyl-1,3-thiazol-2-yl)phenyl]-1-methyl-6-(trifluoromethyl)-2,4(1*H*,3*H*)-pyrimidinedione;

- methyl (2*E*)-4-{2,4-dichloro-5-[1,2,3,6-tetrahydro-3-methyl-2,6-dioxo-4-(trifluoromethyl)pyrimidin-1-yl]phenoxy}-3-methoxypent-2-enoate;

- methyl (2*E*)-4-{2-chloro-4-fluoro-5-[1,2,3,6-tetrahydro-3-methyl-2,6-dioxo-4-(trifluoromethyl)pyrimidin-1-yl]phenoxy}-3-methoxypent-2-enoate;

- ethyl (2*E*)-4-{2,4-dichloro-5-[1,2,3,6-tetrahydro-3-methyl-2,6-dioxo-4-(trifluoromethyl)pyrimidin-1-yl]phenoxy}-3-methoxybut-2-enoate;

- ethyl (2*E*)-4-{2-chloro-4-fluoro-5-[1,2,3,6-tetrahydro-3-methyl-2,6-dioxo-4-(trifluoromethyl)pyrimidin-1-yl]phenoxy}-3-methoxybut-2-enoate;

- 3-{4-chloro-3-[2-(methoxymethyl)-2*H*-tetrazol-5-yl]phenyl}-1-methyl-6-(trifluoromethyl)-2,4(1*H*,3*H*)-pyrimidinedione;
- 3-{4-chloro-3-[1-(methoxymethyl)-1*H*-tetrazol-5-yl]phenyl}-1-methyl-6-(trifluoromethyl)-2,4(1*H*,3*H*)-pyrimidinedione;
- 3-{4-chloro-3-[2-(ethoxymethyl)-2*H*-tetrazol-5-yl]phenyl}-1-methyl-6-(trifluoromethyl)-2,4(1*H*,3*H*)-pyrimidinedione;
- 3-{4-chloro-3-[1-(ethoxymethyl)-1*H*-tetrazol-5-yl]phenyl}-1-methyl-6-(trifluoromethyl)-2,4(1*H*,3*H*)-pyrimidinedione;
- 3-[3-(2-allyl-2*H*-tetrazol-5-yl)-4-chlorophenyl]-1-methyl-6-(trifluoromethyl)-2,4(1*H*,3*H*)-pyrimidinedione;
- 3-[3-(1-allyl-1*H*-tetrazol-5-yl)-4-chlorophenyl]-1-methyl-6-(trifluoromethyl)-2,4(1*H*,3*H*)-pyrimidinedione;
- 3-{4-chloro-2-fluoro-5-[(3-methylisoxazol-5-yl)methoxy]phenyl}-1-methyl-6-(trifluoromethyl)-2,4(1*H*,3*H*)-pyrimidinedione;
- 3-{2,4-dichloro-5-[(3-methylisoxazol-5-yl)methoxy]phenyl}-1-methyl-6-(trifluoromethyl)-2,4(1*H*,3*H*)-pyrimidinedione;
- 3-[4-chloro-3-(4-isopropoxy-5-methyl-1,3-thiazol-2-yl)phenyl]-1-methyl-6-(trifluoromethyl)-2,4(1*H*,3*H*)-pyrimidinedione;
- 3-[4-chloro-3-(4-hydroxy-5-methyl-1,3-thiazol-2-

yl)phenyl-1-methyl-6-(trifluoromethyl)-2,4(1*H*,3*H*)-pyrimidinedione;

- 3-{4-chloro-2-fluoro-5-[(5-methyl-1,2,4-oxadiazol-3-yl)methoxy]phenyl}-1-methyl-6-(trifluoromethyl)-2,4(1*H*,3*H*)-pyrimidinedione;
- 3-{2,4-dichloro-5-[(5-methyl-1,2,4-oxadiazol-3-yl)methoxy]phenyl}-1-methyl-6-(trifluoromethyl)-2,4(1*H*,3*H*)-pyrimidinedione;
- 3-[3-(1,3-benzothiazol-2-yl)-4-chlorophenyl]-1-methyl-6-(trifluoromethyl)-2,4(1*H*,3*H*)-pyrimidinedione;
- 3-[3-(1,3-benzoxazol-2-yl)-4-chlorophenyl]-1-methyl-6-(trifluoromethyl)-2,4(1*H*,3*H*)-pyrimidinedione;
- 3-{4-chloro-2-fluoro-5-[(3-methyl-1,2,4-oxadiazol-5-yl)methoxy]phenyl}-1-methyl-6-(trifluoromethyl)-2,4(1*H*,3*H*)-pyrimidinedione;
- 3-[4-chloro-3-(4-methyl-1,3-thiazol-2-yl)phenyl]-1-methyl-6-(trifluoromethyl)-2,4(1*H*,3*H*)-pyrimidinedione;
- 3-[4-chloro-2-fluoro-5-(1,2,4-oxadiazol-3-ylmethoxy)phenyl]-1-methyl-6-(trifluoromethyl)-2,4(1*H*,3*H*)-pyrimidinedione;
- 3-[3-(2-*tert*-butyl-2*H*-tetrazol-5-yl)-4-chlorophenyl]-1-methyl-6-(trifluoromethyl)-2,4(1*H*,3*H*)-pyrimidinedione;
- 3-[5-(1,3-benzothiazol-2-yl)-4-chloro-2-fluorophenyl]-1-methyl-6-(trifluoromethyl)-2,4(1*H*,3*H*)-pyrimidinedione;

- 3-(4-chloro-3-{2-[(2-methoxyethoxy)methyl]-2*H*-tetrazol-5-yl}phenyl)-1-methyl-6-(trifluoromethyl)-2,4(1*H*,3*H*)-pyrimidinedione;
- 3-(4-chloro-3-{1-[(2-methoxyethoxy)methyl]-1*H*-tetrazol-5-yl}phenyl)-1-methyl-6-(trifluoromethyl)-2,4(1*H*,3*H*)-pyrimidinedione;
- 3-[5-(1,3-benzoxazol-2-yl)-4-chloro-2-fluorophenyl]-1-methyl-6-(trifluoromethyl)-2,4(1*H*,3*H*)-pyrimidinedione;
- 3-[5-(1,3-benzothiazol-2-yl)-2,4-dichlorophenyl]-1-methyl-6-(trifluoromethyl)-2,4(1*H*,3*H*)-pyrimidinedione;
- 3-[2,4-dichloro-5-(6-methyl-1,3-benzoxazol-2-yl)phenyl]-1-methyl-6-(trifluoromethyl)-2,4(1*H*,3*H*)-pyrimidinedione;
- 2-(5-{2-chloro-5-[1,2,3,6-tetrahydro-3-methyl-2,6-dioxo-4-(trifluoromethyl)pyrimidin-1-yl]phenyl}-2*H*-tetrazol-2-yl)-*N,N*-dimethylacetamide;
- 2-(5-{2-chloro-5-[1,2,3,6-tetrahydro-3-methyl-2,6-dioxo-4-(trifluoromethyl)pyrimidin-1-yl]phenyl}-2*H*-tetrazol-2-yl)acetamide;
- 3-[2,4-dichloro-5-(4-methyl-1,3-thiazol-2-yl)phenyl]-1-methyl-6-(trifluoromethyl)-2,4(1*H*,3*H*)-pyrimidinedione;
- 3-[3-(4-*tert*-butyl-1,3-thiazol-2-yl)-4-chlorophenyl]-1-methyl-6-(trifluoromethyl)-2,4(1*H*,3*H*)-pyrimidinedione;
- 3-[2,4-dichloro-5-(4-isobutyl-1,3-thiazol-2-yl)phenyl]-1-methyl-6-(trifluoromethyl)-2,4(1*H*,3*H*)-pyrimidinedione;

- 3-[4-chloro-3-(1,3-thiazol-2-yl)phenyl]-1-methyl-6-(trifluoromethyl)-2,4(1*H*,3*H*)-pyrimidinedione;
- ethyl 2-{2-chloro-5-[1,2,3,6-tetrahydro-3-methyl-2,6-dioxo-4-(trifluoromethyl)pyrimidin-1-yl]phenyl}-4-methyl-1,3-thiazole-5-carboxylate;
- 3-{5-[(3-*tert*-butylisoxazol-5-yl)methoxy]-4-chloro-2-fluorophenyl}-1-methyl-6-(trifluoromethyl)-2,4(1*H*,3*H*)-pyrimidinedione;
- 3-{4-chloro-2-fluoro-5-[(3-isopropylisoxazol-5-yl)methoxy]phenyl}-1-methyl-6-(trifluoromethyl)-2,4(1*H*,3*H*)-pyrimidinedione;
- 3-[4-chloro-3-(2-isopropyl-2*H*-tetrazol-5-yl)phenyl]-1-methyl-6-(trifluoromethyl)-2,4(1*H*,3*H*)-pyrimidinedione;
- 3-[3-(2-benzyl-2*H*-tetrazol-5-yl)-4-chlorophenyl]-1-methyl-6-(trifluoromethyl)-2,4(1*H*,3*H*)-pyrimidinedione;
- 3-[3-(1-benzyl-1*H*-tetrazol-5-yl)-4-chlorophenyl]-1-methyl-6-(trifluoromethyl)-2,4(1*H*,3*H*)-pyrimidinedione;
- 3-{4-chloro-2-fluoro-5-[(1-methyl-1*H*-tetrazol-5-yl)oxy]phenyl}-1-methyl-6-(trifluoromethyl)-2,4(1*H*,3*H*)-pyrimidinedione;
- 3-{4-chloro-2-fluoro-5-[(2-methyl-2*H*-tetrazol-5-yl)oxy]phenyl}-1-methyl-6-(trifluoromethyl)-2,4(1*H*,3*H*)-pyrimidinedione;
- methyl (2*E*)-4-{2-chloro-5-[1,2,3,6-tetrahydro-3-methyl-

2,6-dioxo-4(trifluoromethyl)pyrimidin-1-yl]phenoxy}-3-methoxybut-2-enoate;

- ethyl (2E)-4-{2-chloro-5-[1,2,3,6-tetrahydro-3-methyl-2,6-dioxo-4(trifluoromethyl)pyrimidin-1-yl]phenoxy}-3-ethoxybut-2-enoate;
- 3-[4-chloro-3-(1,2,4-oxadiazol-3-ylmethoxy)phenyl]-1-methyl-6-(trifluoromethyl)-2,4(1H,3H)-pyrimidinedione;
- 3-{4-chloro-3-[(3-methylisoxazol-5-yl)methoxy]phenyl}-1-methyl-6-(trifluoromethyl)-2,4(1H,3H)-pyrimidinedione;
- 3-[4-chloro-3-(4,5,6,7-tetrahydro-1,3-benzothiazol-2-yl)phenyl]-1-methyl-6-(trifluoromethyl)-2,4(1H,3H)-pyrimidinedione;
- 3-[4-chloro-3-(5,6-dihydro-1,4,2-dioxazin-3-yl)phenyl]-1-methyl-6-(trifluoromethyl)-2,4(1H,3H)-pyrimidinedione;
- 3-[4-chloro-3-(4-methyl-5-oxo-5,6-dihydro-4H-1,3,4-oxadiazin-2-yl)phenyl]-1-methyl-6-(trifluoromethyl)-2,4(1H,3H)-pyrimidinedione;
- 3-[4-chloro-3-(5,6-dihydro-1,4,2-dioxazin-3-ylmethoxy)-2-fluorophenyl]-1-methyl-6-(trifluoromethyl)-2,4(1H,3H)-pyrimidinedione;
- 3-{4-chloro-2-fluoro-5-[(4-methyl-5-oxo-5,6-dihydro-4H-1,3,4-oxadiazin-2-yl)methoxy]phenyl}-1-methyl-6-(trifluoromethyl)-2,4(1H,3H)-pyrimidinedione;
- 3-[4-chloro-3-(2-phenyl-2H-tetrazol-5-yl)phenyl]-1-

methyl-6-(trifluoromethyl)-2,4(1*H*,3*H*)-pyrimidinedione;
 - 3-[4-chloro-3-(1-phenyl-1*H*-tetrazol-5-yl)phenyl]-1-methyl-6-(trifluoromethyl)-2,4(1*H*,3*H*)-pyrimidinedione;
 - 3-{4-chloro-3-[1-(cyclopropylmethyl)-1*H*-tetrazol-5-yl]phenyl}-1-methyl-6-(trifluoromethyl)-2,4(1*H*,3*H*)-pyrimidinedione;
 - 3-{4-chloro-3-[2-(cyclopropylmethyl)-2*H*-tetrazol-5-yl]phenyl}-1-methyl-6-(trifluoromethyl)-2,4(1*H*,3*H*)-pyrimidinedione;
 - 3-{4-chloro-3-[1-(2-oxopropyl)-1*H*-tetrazol-5-yl]phenyl}-1-methyl-6-(trifluoromethyl)-2,4(1*H*,3*H*)-pyrimidinedione;
 - 3-{4-chloro-3-[2-(2-oxopropyl)-2*H*-tetrazol-5-yl]phenyl}-1-methyl-6-(trifluoromethyl)-2,4(1*H*,3*H*)-pyrimidinedione;
 - 3-[4-chloro-3-(4-cyclopropyl-1,3-thiazol-2-yl)phenyl]-1-methyl-6-(trifluoromethyl)-2,4(1*H*,3*H*)-pyrimidinedione;
 - 3-{4-chloro-3-[4-(4-chlorophenyl)-1,3-thiazol-2-yl]phenyl}-1-methyl-6-(trifluoromethyl)-2,4(1*H*,3*H*)-pyrimidinedione;
 - ethyl 2-{2-chloro-5-[1,2,3,6-tetrahydro-3-methyl-2,6-dioxo-4-(trifluoromethyl)pyrimidin-1-yl]phenyl}-1,3-thiazole-4-carboxylate;
 - 3-[3-(2-butyl-2*H*-tetrazol-5-yl)-4-chlorophenyl]-1-methyl-6-(trifluoromethyl)-2,4(1*H*,3*H*)-pyrimidinedione;
 -3-[4-chloro-2-fluoro-5-(5,6-dihydro-1,4,2-dioxazin-3-

ylmethoxy)-2-fluorophenyl]-1-methyl-6-(trifluoromethyl)-
2,4(1*H*,3*H*)-pyrimidinedione;


- 3-(4-chloro-3-{2-[(4-chlorophenoxy)methyl]-2*H*-tetrazol-5-yl}phenyl)-1-methyl-6-(trifluoromethyl)-2,4(1*H*,3*H*)-
pyrimidinedione;
- 3-(4-chloro-3-{1-[(4-chlorophenoxy)methyl]-1*H*-tetrazol-5-yl}phenyl)-1-methyl-6-(trifluoromethyl)-2,4(1*H*,3*H*)-
pyrimidinedione;
- 3-[3-(4-*tert*-butyl-5-oxo-4,5-dihydro-1,3,4-thiadiazol-2-yl)-4-chlorophenyl]-1-methyl-6-(trifluoromethyl)-
2,4(1*H*,3*H*)-pyrimidinedione;
- 3-{4-chloro-3-[2-(4-chlorobenzyl)-2*H*-tetrazol-5-yl]phenyl}-1-methyl-6-(trifluoromethyl)-2,4(1*H*,3*H*)-
pyrimidinedione;
- 3-{4-chloro-3-[1-(4-chlorobenzyl)-1*H*-tetrazol-5-yl]phenyl}-1-methyl-6-(trifluoromethyl)-2,4(1*H*,3*H*)-
pyrimidinedione;
- methyl 2-{2-chloro-5-[1,2,3,6-tetrahydro-3-methyl-2,6-dioxo-4-(trifluoromethyl)pyrimidin-1-yl]phenyl}-1,3-thiazole-4-carboxylate;
- methyl (2-{2-chloro-5-[1,2,3,6-tetrahydro-3-methyl-2,6-dioxo-4-(trifluoromethyl)pyrimidin-1-yl]phenyl}-1,3-thiazol-4-yl)acetate.

3. (original):The uracils according to claim 1

characterized in that they are compounds having formula (I) isomerically pure, or in an isomeric mixture in any proportion.

4. (previously presented): A process for the preparation of compounds having general formula (I) according to claim 1, characterized in that it includes a cyclo-condensation reaction of an isocyanate or isothiocyanate having general formula (II) with a 3-aminocrotonate having general formula (III) according to reaction scheme 1

Scheme 1:




wherein

- X_1 , X_2 , X_3 , X_4 , R and G have the meanings previously defined;
- R_{13} represents a C_1 - C_4 alkyl or C_1 - C_4 haloalkyl group or a phenyl group possibly substituted with C_1 - C_4 alkyl groups.

5. (original) The process according to claim 4, characterized in that the reaction is carried out in the presence of an inert organic solvent and in the presence of an organic base or preferably inorganic base, at a temperature ranging from -20°C to the boiling point of the reaction mixture.

6. (original): The process according to claim 4, characterized in that the isocyanates or isothiocyanates having general formula (II) are prepared starting from a substituted aniline having general formula (IV) by reaction with a compound having general formula (V), such as phosgene, diphosgene, triphosgene or thiophosgene, according to reaction scheme 2

Scheme 2:




wherein

- X_1 , X_2 , X_3 and G have the meanings defined above;

- L_3 and L_4 , the same or different, represent a chlorine atom or a CCl_3O- group.

7. (original): The process according to claim 6, characterized in that the reaction is carried out in the presence of an inert organic solvent, at a temperature ranging from 0°C to the boiling point of the mixture itself, possibly in the presence of a catalyst such as triethylamine, in an amount ranging from 0.001 and 100% by weight with respect to the aniline (IV), with a quantity of reagent (V) varying from 1 to 3 moles per mole of aniline (IV).

8. (previously presented): The process for the preparation of compounds having general formula (I) according to claim 1, wherein X_3 represents a $Q(CR_1R_2)_nZ-$ group, a Q_1Z- group, a $Y(OC)-CR_6=CR_5-CR_3R_4Z-$ group, compounds (Ia), characterized in that it comprises the reaction of a uracil having general formula (VI) with a compound having general formula (VII) according to reaction scheme 3



Scheme 3:

wherein


- X_1 , X_2 , X_4 , G and Z have the meanings previously defined;
- R represents a C_1 - C_3 alkyl group or a C_1 - C_3 haloalkyl group;
- W represents a $Q(CR_1R_2)_n$ - group, a Q_1 - group, a $Y(OC)-CR_6=CR_5-CR_3R_4$ - group, wherein R_1 , R_2 , R_3 , R_4 , R_5 , R_6 , Y, Q and Q_1 have the meanings defined above;
- L_2 represents a halogen atom, a R_LSO_2O - group, wherein R_L represents a C_1 - C_4 alkyl or C_1 - C_4 haloalkyl group or a phenyl group possibly substituted by C_1 - C_4 alkyl groups, or it represents a $R_{L1}SO_2$ - group wherein R_{L1} represents a C_1 - C_4

alkyl or C₁-C₄ haloalkyl group.

9. (previously presented): The process according to claim 8, characterized in that the reaction between the compounds having general formula (VI) and the compounds having general formula (VII) is carried out in the presence of one or more inert organic solvent(s) and in the presence of a base, preferably an inorganic base, at a temperature ranging from -10°C to the boiling point of the reaction mixture.

10. (previously presented): The process for the preparation of the compounds having general formula (I) according to claim 1, wherein G = O and R ≠ H, compounds (Ic), characterized in that it comprises the reaction of a uracil having general formula (Ib) with an alkylating compound having general formula (VIII) according to reaction scheme 4

Scheme 4:



wherein


- X_1 , X_2 , X_3 and X_4 have the meanings defined above;
- R' represents a C_1 - C_3 alkyl or C_1 - C_3 haloalkyl group;
- L_1 represents a halogen atom, or a $R_L\text{SO}_2\text{O}-$ group wherein R_L represents a C_1 - C_4 alkyl or C_1 - C_4 haloalkyl group or a phenyl group possibly substituted by C_1 - C_4 alkyl groups.

11. (previously presented): The process according to claim 10, characterized in that the reaction between the compounds having general formula (Ib) and the compound having general formula (VIII) is carried out in the presence of one or more inert organic solvents and in the presence of a base, preferably an inorganic base, at a temperature ranging from -10°C to the boiling point of the reaction mixture.

12. (previously presented): The process according to claim 8, characterized in that the reaction is carried out in a biphasic system using water as solvent and an organic solvent immiscible with water, in the presence of phase transfer catalysts.

13. (previously presented): The process for the preparation of compounds having general formula (I) according to claim 1, wherein $G=O$, compounds (Id), characterized in that it comprises a first reaction between a substituted aniline having formula (IV) and a chloroformate or a carbonate having formula (IX) to give a carbamate having formula (X) and a second reaction wherein the carbamate is converted into the compounds having general formula (Id) by cyclo-condensation with a 3-aminocrotonate having general formula (III), according to reaction scheme 5:

Scheme 5:



wherein

- X_1 , X_2 , X_3 , X_4 and R have the meanings defined above;
- L_5 represents a halogen atom or a OR_{14} group;
- R_{13} and R_{14} represent a C_1 - C_4 alkyl or C_1 - C_4 haloalkyl group or a phenyl group possibly substituted by C_1 - C_4 alkyl groups.

14. (previously presented): The process according to claim 13, characterized in that the first reaction is carried out

in the presence of an inert organic solvent, at a temperature ranging from -10°C to the boiling point of the mixture itself, in the presence of an organic or inorganic base, in a quantity varying from 1 to 1.5 moles per mole of aniline (IV), with a quantity of compound having formula (IX) varying from 1 to 1.5 moles per mole of aniline (IV).


15. (currently amended) The process according to claim 13, characterized in that the cyclo-condensation reaction of the carbamate having general formula (X) with the 3-aminocrotonate having general formula (III) is carried out in the presence of an inert organic solvent and in the presence of an organic or preferably inorganic base, at a temperature ranging from -20°C to the boiling point of the reaction mixture.

16. (previously presented): The process according to claim 10, characterized in that the compounds having general formula (Ib) are prepared starting from an aniline having general formula (IV) by reaction with a β -ketoester having general formula (XII), to give an anilide having general formula (XIII), then converted into the intermediate of general formula (XIV) by amination with ammonia or ammonium salts, said intermediate being converted into the compounds of general formula (Ib) by cyclization with a compound of general formula (XV), such

as phosgene, or diphosgene according to the reaction scheme

6

Scheme 6:



wherein:

- X_1 , X_2 , X_3 and X_4 have the meanings defined above;
- R_{13} represents a C_1 - C_4 alkyl or haloalkyl group or a phenyl group possibly substituted by C_1 - C_4 alkyl groups;
- L_6 and L_7 , having the same or different meaning, represent a chlorine atom, a CCl_3O- group, a C_1 - C_4 alkoxy group, a phenoxy group, an imidazol-1-yl group or a 1,2,4-triazol-1-yl group.

17. (previously presented): The process according to

claim 16, characterised in that the reaction between the compounds having general formula (IV) and the compounds having general formula (XII) is carried out in the presence of one or more inert organic solvents, at a temperature ranging from -10°C to the boiling temperature of the reaction mixture, using an amount of compound (XII) ranging from 1 to 3 moles per mole of aniline (IV).

18. (previously presented): (currently amended) The process according to claim 17, characterised in that the reaction is carried out while distilling off compound R_{13}OH formed during the reaction, alone or in mixture with the solvent used.

19. (previously presented): The process according to claim 16, characterised in that the transformation of compounds having general formula (XIII) into compounds having general formula (XIV) is carried out in the presence of one or more inert organic solvents, at a temperature ranging from -10°C to the boiling temperature of the reaction mixture, using ammonia or an ammonium salt, in an amount ranging from 1 to 20 moles per mole of compound (XIII).

20. (previously presented): The process according to claim 16, characterised in that the reaction between the compounds having general formula (XIV) and the compounds

and the compounds having general formula (XV) is carried out in the presence of one or more inert organic solvents, at a temperature ranging from -10°C to the boiling temperature of the reaction mixture, using an amount of compound (XV) ranging from 1 to 5 moles per mole of compound (XIV) in the presence of a suitable organic or inorganic base, in an amount ranging from 1 to 5 moles per mole of compound (XIV).

21. (previously presented):) Use of uracils having general formula (I) according to claims 1, as herbicides.

22.(original) Use according to claim 21 for the pre-emergence and/or post-emergence control of monocotyledonous or dicotyledonous weeds.

23. (previously presented): Method for the control of weeds in cultivated areas by the application of the compounds having general formula (I) according to claims 1.

24. (original)(The method according to claim 23, characterized in that the amount of compound having formula (I) to be applied varies between dosages of compounds ranging from 1g to 1000g per hectare.

25. (previously presented): The herbicidal compositions containing, as active principle, one or more compounds having general formula (I) according to claim 1, possibly

also as a blend of isomers.

26. (original) The herbicidal compositions according to claim 25, comprising other active principles which are compatible with the compounds having general formula (I), such as other herbicides, fungicides, insecticides, acaricides, fertilizers, etc..

27. (original) The herbicidal compositions according to claim 25, characterized in that the further herbicides are selected from:

acetochlor, acifluorfen, aclonifen, AKH-7088, alachlor, alloxydim, ametryn, amicarbazone, amidosulfuron, amitrole, anilofos, asulam, atrazine, azafenidin, azimsulfuron, aziprotryne, BAY MKH 6561, beflubutamid, benazolin, benfluralin, benfuresate, bensulfuron, bensulide, bentazone, benzfendizone, benzobicyclon, benzofenap, benzthiazuron, bifenox, bilanafos, bispribac-sodium, bromacil, bromobutide, bromofenoxim, bromoxynil, butachlor, butafenacil, butamifos, butenachlor, butralin, butroxydim, butylate, cafenstrole, carbetamide, carfentrazone-ethyl, chlomethoxyfen, chloramben, chlorbromuron, chlorbufam, chlorflurenol, chloridazon, chlorimuron, chlornitrofen, chlorotoluron, chloroxuron, chlorpropham, chlorsulfuron, chlorthal, chlorthiamid, cinidon ethyl, cinmethylin, cinosulfuron, clethodim, clodinafop, clomazone, clomeprop,

clopyralid, cloransulam-methyl, cumyluron (JC-940),
cyanazine, cycloate, cyclosulfamuron, cycloxydim,
cyhalofop-butyl, 2,4-D, 2,4-DB, daimuron, dalapon,
desmedipham, desmetryn, dicamba, dichlobenil, dichlorprop,
dichlorprop-P, diclofop, diclosulam, diethatyl,
difenoxuron, difenzoquat, diflufenican, diflufenzopyr,
dimefuron, dimepiperate, dimethachlor, dimethametryn,
dimethenamid, dinitramine, dinoseb, dinoseb acetate,
dinoterb, diphenamid, dipropetryn, diquat, dithiopyr, 1-
diuron, eglinazine, endothal, EPTC, esprocarb,
ethalfluralin, ethametsulfuron-methyl, ethidimuron,
ethiozin (SMY 1500), ethofumesate, ethoxyfen-ethyl (HC-
252), ethoxysulfuron, etobenzanid (HW 52), fenoxaprop,
fenoxaprop-P, fentrazamide, fenuron, flamprop, flamprop-M,
flazasulfuron, florasulam, fluazifop, fluazifop-P,
fluazolate (JV 485), flucarbazone-sodium, fluchloralin,
flufenacet, flufenpyr ethyl, flumetsulam, flumiclorac-
pentyl, flumioxazin, flumipropin, fluometuron,
fluoroglycofen, fluoronitrofen, flupoxam, flupropanate,
flupyrsulfuron, flurenol, fluridone, flurochloridone,
fluroxypyr, flurtamone, fluthiacet-methyl, fomesafen,
foramsulfuron, fosamine, furyloxyfen, glufosinate,
glyphosate, halosulfuron-methyl, haloxyfop, haloxyfop-P-
methyl, hexazinone, imazamethabenz, imazamox, imazapic,

imazapyr, imazaquin, imazethapyr, imazosulfuron, indanofan, iodosulfuron, ioxynil, isopropalin, isoproturon, isouron, isoxaben, isoxachlortole, isoxaflutole, isoxapyrifop, KPP-421, lactofen, lenacil, linuron, LS830556, MCPA, MCPA-thioethyl, MCPB, mecoprop, mecoprop-P, mefenacet, mesosulfuron, mesotrione, metamitron, metazachlor, methabenzthiazuron, methazole, methoprotryne, methyldymron, metobenzuron, metobromuron, metolachlor, S-metolachlor, metosulam, metoxuron, metribuzin, metsulfuron, molinate, monalide, monolinuron, naproanilide, napropamide, naptalam, NC-330, neburon, nicosulfuron, nipyraclufen, norflurazon, orbencarb, oryzalin, oxadiargyl, oxadiazon, oxasulfuron, oxaziclomefone, oxyfluorfen, paraquat, pebulate, pendimethalin, penoxsulam, pentanochlor, pentoxazone, pethoxamid, phenmedipham, picloram, picolinafen, piperophos, pretilachlor, primisulfuron, prodiamine, profluazol, proglinazine, prometon, prometryne, propachlor, propanyl, propaquizafop, propazine, propham, propisochlor, propyzamide, prosulfocarb, prosulfuron, pyraclonil, pyraflufen-ethyl, pyrazogyl (HSA-961), pyrazolynate, pyrazosulfuron, pyrazoxyfen, pyribenzoxim, pyributicarb, pyridafol, pyridate, pyriftalid, pyriminobac-methyl, pyriothiobac-sodium, quinclorac, quinmerac, quizalofop, quizalofop-P, rimsulfuron, sethoxydim, siduron, simazine,

simetryn, sulcotrione, sulfentrazone, sulfometuron-methyl, sulfosulfuron, 2,3,6-TBA, TCA-sodium, tebutam, tebuthiuron, tepraloxydim, terbacil, terbumeton, terbuthyl-azine, terbutryn, thenylchlor, thiazafluron, thiazopyr, thidiazimin, thifensulfuron-methyl, thiobencarb, tiocarbazil, tioclorim, tralkoxydim, tri-allate, triasulfuron, triaziflam, tribenuron, triclopyr, trietazine, trifloxysulfuron, trifluralin, triflusulfuron-methyl, tritosulfuron, UBI-C4874, vernolate.

28. (previously presented): The compositions according to claim 25, characterized in that the concentration of the active substance ranges from 1 to 90%.